For immediate release 26 May 2016 AFSTYLA® (rFVIII-Single Chain) – FDA approval CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemo - Prescription - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-05-25 20:22:52 Haemophilia Coagulation system CSL Behring Recombinant proteins CSL Limited Factor VIII CSL Coagulation		For immediate release 26 May 2016 AFSTYLA® (rFVIII-Single Chain) – FDA approval CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemo Add to Reading List Source URL: www.csl.com.au Download Document from Source Website File Size: 52,73 KB Share Document on Facebook

	Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave. DocID: 1riKA - View Document
	Microsoft Wordfile00 DocID: 1r9dZ - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1qHpD - View Document
	RECOTHROM, Thrombin topical (Recombinant) Package Insert DocID: 1qv5K - View Document
	Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve DocID: 1qk7W - View Document